
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14D-9

**SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

Forma Therapeutics Holdings, Inc.
(Name of Subject Company)

Forma Therapeutics Holdings, Inc.
(Name of Persons Filing Statement)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE
(Title of Class of Securities)
34633R104
(CUSIP Number of Class of Securities)

Frank D. Lee
Forma Therapeutics Holdings, Inc.
President & Chief Executive Officer
300 North Beacon Street
Suite 501
Watertown, Massachusetts 02472
(617) 679-1970

With copies to:

Stuart M. Cable, Esq.
Lisa R. Haddad, Esq.
William D. Collins, Esq.
Andrew H. Goodman, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000

(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Forma Therapeutics Holdings, Inc. on September 1, 2022 (including all exhibits attached thereto) is incorporated herein by reference.
